Article: Inhaled fluticasone in bronchiectasis: A 12 month study

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleInhaled fluticasone in bronchiectasis: A 12 month study
AuthorsTsang, KW1
Tan, KC1
Ho, PL1
Ooi, GC1
Ho, JC1
Mak, J1
Tipoe, GL1
Ko, C1
Yan, C1
Lam, WK1
ChanYeung, M1
Issue Date2005
PublisherB M J Publishing Group. The Journal's web site is located at http://thorax.bmjjournals.com/
CitationThorax, 2005, v. 60 n. 3, p. 239-243 [How to Cite?]
DOI: http://dx.doi.org/10.1136/thx.2002.003236
AbstractBackground: The clinical efficacy of inhaled corticosteroid (ICS) treatment has not been evaluated in bronchiectasis, despite the presence of chronic airway inflammation. Methods: After three consecutive weekly visits, 86 patients were randomised to receive either fluticasone 500 μ9 twice daily (n = 43, 23F, mean (SD) age 57.7 (14.4) years) or matched placebo (n = 43, 34F, 59.2 (14.2) years) and reviewed regularly for 52 weeks in a double blind fashion. Results: 35 and 38 patients in the fluticasone and placebo groups completed the study. Significantly more patients on ICS than on placebo showed improvement in 24 hour sputum volume (OR 2.5, 95% CI 1.1 to 6.0, p = 0.03) but not in exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score. Significantly more patients with Pseudomonas aeruginosa infection receiving fluticasone showed improvement in 24 hour sputum volume (OR 13.5, 95% CI 1.8 to 100.2, p = 0.03) and exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01 ) than those given placebo. Logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume <30 ml (p = 0.04), exacerbation frequency ≤2/year (p = 0.04), and sputum purulence score >5 (p = 0.03). Conclusions: ICS treatment is beneficial to patients with bronchiectasis, particularly those with P aerurginosa infection.
ISSN0040-6376
2011 Impact Factor: 6.84
2011 SCImago Journal Rankings: 0.429
DOIhttp://dx.doi.org/10.1136/thx.2002.003236
PubMed Central IDPMC1747352
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorTsang, KW
dc.contributor.authorTan, KC
dc.contributor.authorHo, PL
dc.contributor.authorOoi, GC
dc.contributor.authorHo, JC
dc.contributor.authorMak, J
dc.contributor.authorTipoe, GL
dc.contributor.authorKo, C
dc.contributor.authorYan, C
dc.contributor.authorLam, WK
dc.contributor.authorChanYeung, M
dc.date.accessioned2007-01-08T02:27:02Z
dc.date.available2007-01-08T02:27:02Z
dc.date.issued2005
dc.description.abstractBackground: The clinical efficacy of inhaled corticosteroid (ICS) treatment has not been evaluated in bronchiectasis, despite the presence of chronic airway inflammation. Methods: After three consecutive weekly visits, 86 patients were randomised to receive either fluticasone 500 μ9 twice daily (n = 43, 23F, mean (SD) age 57.7 (14.4) years) or matched placebo (n = 43, 34F, 59.2 (14.2) years) and reviewed regularly for 52 weeks in a double blind fashion. Results: 35 and 38 patients in the fluticasone and placebo groups completed the study. Significantly more patients on ICS than on placebo showed improvement in 24 hour sputum volume (OR 2.5, 95% CI 1.1 to 6.0, p = 0.03) but not in exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score. Significantly more patients with Pseudomonas aeruginosa infection receiving fluticasone showed improvement in 24 hour sputum volume (OR 13.5, 95% CI 1.8 to 100.2, p = 0.03) and exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01 ) than those given placebo. Logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume <30 ml (p = 0.04), exacerbation frequency ≤2/year (p = 0.04), and sputum purulence score >5 (p = 0.03). Conclusions: ICS treatment is beneficial to patients with bronchiectasis, particularly those with P aerurginosa infection.
dc.description.naturepublished_or_final_version
dc.format.extent101963 bytes
dc.format.extent25088 bytes
dc.format.extent618083 bytes
dc.format.extent4522 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypeapplication/msword
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.identifier.citationThorax, 2005, v. 60 n. 3, p. 239-243 [How to Cite?]
DOI: http://dx.doi.org/10.1136/thx.2002.003236
dc.identifier.doihttp://dx.doi.org/10.1136/thx.2002.003236
dc.identifier.epage243
dc.identifier.hkuros117978
dc.identifier.isiWOS:000227470700016
dc.identifier.issn0040-6376
2011 Impact Factor: 6.84
2011 SCImago Journal Rankings: 0.429
dc.identifier.issue3
dc.identifier.openurl
dc.identifier.pmcidPMC1747352
dc.identifier.pmid15741443
dc.identifier.scopuseid_2-s2.0-20144377363
dc.identifier.spage239
dc.identifier.urihttp://hdl.handle.net/10722/42019
dc.identifier.volume60
dc.languageeng
dc.publisherB M J Publishing Group. The Journal's web site is located at http://thorax.bmjjournals.com/
dc.publisher.placeUnited Kingdom
dc.relation.ispartofThorax
dc.relation.referencesReferences in Scopus
dc.rightsThorax. Copyright © B M J Publishing Group.
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.subject.meshAdministration, inhalation
dc.subject.meshAndrostadienes - administration & dosage
dc.subject.meshBronchiectasis - drug therapy
dc.subject.meshForced expiratory volume - physiology
dc.subject.meshVital capacity
dc.titleInhaled fluticasone in bronchiectasis: A 12 month study
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong